Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.

Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.

PMID:
29093017
2.

Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.

McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.

PLoS One. 2016 Mar 8;11(3):e0151121. doi: 10.1371/journal.pone.0151121. eCollection 2016. No abstract available.

3.

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.

McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.

PLoS One. 2015 Sep 1;10(9):e0136851. doi: 10.1371/journal.pone.0136851. eCollection 2015. Erratum in: PLoS One. 2016;11(3):e0151121.

4.

Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.

Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J.

Endocr Relat Cancer. 2015 Jun;22(3):431-41. doi: 10.1530/ERC-15-0002. Epub 2015 Apr 21.

5.

SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.

Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F.

J Natl Cancer Inst. 2015 Feb 16;107(3). pii: dju493. doi: 10.1093/jnci/dju493. Print 2015 Mar.

6.

Influence of biospecimen variables on proteomic biomarkers in breast cancer.

Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB.

Clin Cancer Res. 2014 Jul 15;20(14):3870-83. doi: 10.1158/1078-0432.CCR-13-1507. Epub 2014 Jun 3.

7.

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F.

Ann Oncol. 2014 Jun;25(6):1122-7. doi: 10.1093/annonc/mdu124. Epub 2014 Mar 24.

8.

Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.

Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.

Clin Cancer Res. 2012 Oct 15;18(20):5816-28. doi: 10.1158/1078-0432.CCR-12-1141. Epub 2012 Aug 29.

9.

Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.

Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Petricoin EF 3rd, Calvert VS, Fodale V, Wang J, Weber RS.

Am J Pathol. 2011 Feb;178(2):548-71. doi: 10.1016/j.ajpath.2010.10.044.

10.

Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.

Gong Y, Sweet W, Duh YJ, Greenfield L, Tarco E, Trivedi S, Symmans WF, Isola J, Sneige N.

Am J Clin Pathol. 2009 Aug;132(2):228-36. doi: 10.1309/AJCP4M2VUZCLDALN.

PMID:
19605817
12.

Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.

Gong Y, Sweet W, Duh YJ, Greenfield L, Fang Y, Zhao J, Tarco E, Symmans WF, Isola J, Sneige N.

Am J Clin Pathol. 2009 Apr;131(4):490-7. doi: 10.1309/AJCPI00TVGIGYXAA.

PMID:
19289584
13.

HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer.

Kawamoto T, Krishnamurthy S, Tarco E, Trivedi S, Wistuba II, Li D, Roa I, Roa JC, Thomas MB.

Gastrointest Cancer Res. 2007 Nov;1(6):221-7.

14.

A human papillomavirus testing system in women with abnormal Pap results: a comparison study with follow-up biopsies.

Guo M, Patel SJ, Chovanec M, Jan YJ, Tarco E, Bevers TB, Anderson K, Sneige N.

Acta Cytol. 2007 Sep-Oct;51(5):749-54.

PMID:
17910345
15.

Supplemental Content

Support Center